在法布里病中,白质的潜伏性退化和认知衰退是法布里病的潜伏性退化
Jacob W Johnson1, Hediyeh Baradaran2, Jubel Morgan2
1Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah, United States of America.
PloS one
|November 17, 2025
概括
费布里病导致早期白质损伤和认知衰退,与典型的大脑衰老不同. 定量MRI揭示了微结构损伤,强调了老年患者认知监测的必要性.
科学领域:
- 神经学 神经学
- 神经成像是一种神经成像.
- 遗传学 遗传学 是一个
背景情况:
- 法布里病是一种X链 lysosomal储存障碍,导致糖脂积累.
- 神经学并发症包括认知能力下降和白质病变 (WMLs).
- 一般人群中的WML是非特异性的,因此很难辨别出Fabry特异性的变化.
研究的目的:
- 为了区分与法布里病相关的认知衰退与典型的大脑衰老.
- 确定有助于法布里病认知障碍的独特因素.
- 研究法布里患者的白质完整性及其与认知的关系.
主要方法:
- 病例对照研究比较20名法布里患者与20名年龄/性别匹配的健康对照.
- 使用神经认知评估和先进的3.0T脑MRI技术 (sMRI,qMRI,DTI,BPF成像).
- 对结构MRI的盲目审查和对白质微观结构完整性的定量分析.
主要成果:
- 法布里病的结构性MRI特征与正常衰老无法区分.
- 定量核磁共振 (MRI) 揭示了年轻的Fabry成年人 (<40岁) 中微结构性白质损伤.
- 费布里患者的WML严重程度和体缩的年龄依赖性增加,以及口头智商和执行功能的趋势/显著下降.
结论:
- 在法布里病中早期的微观结构性白质损伤驱动着渐进的退化和认知障碍.
- 与Fabry相关的大脑变化与典型的与年龄相关的变化不同,特别是在年轻人中.
- 老化Fabry患者可能会从定期的认知评估中受益,以满足不断变化的治疗需求.
相关概念视频
03:03Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K
03:03Amyloid Fibrils
6.3K
6.3K
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:30Dementia
498
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
498
01:22Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
01:30Cognitive Development During Adulthood
752
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
752